Activity Number:
|
35
- Stories from COVID-19 Vaccine Development: Statistical Challenges and Opportunities
|
Type:
|
Invited
|
Date/Time:
|
Sunday, August 8, 2021 : 3:30 PM to 5:20 PM
|
Sponsor:
|
Biopharmaceutical Section
|
Abstract #315497
|
|
Title:
|
Statistical Observations on Vaccine Clinical Development for Pandemic Diseases
|
Author(s):
|
Scott Patterson* and Bo Fu and Fabrice Bailleux and Josh Chen
|
Companies:
|
Sanofi Pasteur and Sanofi Pasteur and Sanofi Pasteur and Sanofi Pasteur
|
Keywords:
|
SARS-CoV-2;
COVID-19;
efficacy;
safety;
vaccine;
crisis
|
Abstract:
|
Traditional vaccine clinical development is an undertaking involving meticulous, multiple studies in multiple populations at risk of infection and disease over multiple years. SARS-CoV-2 and COVID-19 vaccine development is following this traditional development pathway, and accelerated Phase I-II-III clinical programs are being applied. This is not the first time vaccines have been manufactured and tested quickly to meet a public health crisis. Selected statistical concepts pertaining to vaccine efficacy and safety, relevant during the design and implementation of such clinical development programs, will be discussed.
|
Authors who are presenting talks have a * after their name.